Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival. In circulating cell-free tumour DNA of patients treated with anti-EGFR antibodies, RAS mutations emerge earlier than EGFR ECD variants. Subclonal RAS but not EGFR ECD mutations are present in CRC samples obtained before exposure to EGFR blockade. These data indicate that clonal evolution of drug-resistant cells is associated with the clinical outcome of CRC patients treated with anti-EGFR antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preexisting RAS mutations driving EGFR-independent signaling are seen in intrinsic resistance, whereas the emergence of secondary KRAS mutations or resistant subclonal populations’ expansion during treatment is observed in acquired resistance [13].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [67]
Experimental — accuracy not yet measuredIn the citing paper
“A growing number of studies suggest that mutations in the extracellular domain (ECD) of the EGFR, such as S492R, G465E, R451C and K467T, prevent binding cetuximab and make CRC resistant to anti-EGFR mAbs [141,142,143,144].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Research works printed but not linked: 1
- Whitehead, R. H., Macrae, F. A., St Sohn, D. J. & Ma, J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Natl Cancer Inst. 74, 759–765 (1985).
Cited by
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Emerging functions of the EGFR in cancer
Sigismund, S., Avanzato, D., & Lanzetti, L. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12155 · Cited by 1,469
Liquid Biopsy: From Discovery to Clinical Application
Alix-Panabières, C., & Pantel, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1311 · Cited by 953
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Self-citationCremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Self-citationDasari, A., Morris, V. K., Allegra, C. J., Atreya, C., Benson, A. B., Boland, P., Chung, K., Copur, M. S., Corcoran, R. B., Deming, D. A., et al. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0392-0 · Cited by 372
Self-citationHow liquid biopsies can change clinical practice in oncology
Siravegna, G., Mussolin, B., Venesio, T., Marsoni, S., Seoane, J., Dive, C., Papadopoulos, N., Kopetz, S., Corcoran, R. B., Siu, L. L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz227 · Cited by 358
Self-citationVidal, J., Muinelo, L., Dalmases, A., Jones, F., Edelstein, D., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 344
Self-citationOvercoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L., McKinney, M., Korn, W. M., Atreya, C. E., Banks, K. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1009 · Cited by 295
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
Parseghian, C. M., Loree, J. M., Morris, V. K., Liu, X., Clifton, K. K., Napolitano, S., Henry, J. T., Pereira, A. A., Vilar, E., Johnson, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy509 · Cited by 253
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Precision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Self-citationCruz, E., & Kayser, V. (2019) · Biologics: Targets and Therapy · doi:10.2147/btt.s166310 · Cited by 221
Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Mateos, J. F., Vatsiou, A., Lampis, A., Damavandi, M. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0891 · Cited by 225
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02903 · Cited by 208
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
García-Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 201
Tumor Evolution as a Therapeutic Target
Amirouchene-Angelozzi, N., Swanton, C., & Bardelli, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0343 · Cited by 194
Self-citationCirculating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Cheng, M. L., Pectasides, E., Hanna, G. J., Parsons, H. A., Choudhury, A. D., & Oxnard, G. R. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21650 · Cited by 193
Pietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182
Self-citationSexual Dimorphism in Colon Cancer
Abancens, M., Bustos, V., Harvey, H., McBryan, J., & Harvey, B. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.607909 · Cited by 176
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Siravegna, G., Lazzari, L., Crisafulli, G., Sartore-Bianchi, A., Mussolin, B., Cassingena, A., Martino, C., Lanman, R. B., Nagy, R. J., Fairclough, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.004 · Cited by 159
Self-citationMontagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135
“Age, mean (SD)a, y 62 (10) 64 (10) 61 (11)”
Self-citationZhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby007 · Cited by 154
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 138
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Acar, A., Nichol, D., Fernández-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15596-z · Cited by 150
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01254 · Cited by 111
Self-citationHan, W., Shi, L., Ren, L., Zhou, L., Li, T., Qiao, Y., & Wang, H. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0019-4 · Cited by 106
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
Mangiapane, L. R., Nicotra, A., Turdo, A., Gaggianesi, M., Bianca, P., Franco, S. D., Sardina, D. S., Veschi, V., Signore, M., Beyes, S., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323553 · Cited by 110
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 115
The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
Reece, M. M., Saluja, H., Hollington, P., Karapetis, C. S., Vatandoust, S., Young, G. P., & Symonds, E. L. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01118 · Cited by 103
Recent advances in circulating nucleic acids in oncology
Otandault, A., Anker, P., Dache, Z. A. A., Guillaumon, V., Meddeb, R., Pastor, B., Pisareva, E., Sánchez, C., Tanos, R., Tousch, G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz031 · Cited by 97
Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer
Arisi, M. F., Dotan, E., & Fernandez, S. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084441 · Cited by 103
Parseghian, C. M., Sun, R., Woods, M. N., Napolitano, S., Lee, H. M., Alshenaifi, J. Y., Willis, J. A., Nunez, S., Raghav, K. P. S., Morris, V. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01423 · Cited by 91
Osumi, H., Shinozaki, E., Takeda, Y., Wakatsuki, T., Ichimura, T., Saiura, A., Yamaguchi, K., Takahashi, S., Noda, T., & Zembutsu, H. (2018) · Cancer Medicine · doi:10.1002/cam4.1913 · Cited by 87
Parasrampuria, D. A., Benet, L. Z., & Sharma, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0204-y · Cited by 93
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taieb, J., Jung, A., Sartore-Bianchi, A., Peeters, M., Seligmann, J., Zaanan, A., Burdon, P., Montagut, C., & Laurent-Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 76
Self-citationYang, J., Guo, X., Wang, M., Ma, X., Ye, X., & Lin, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-17130-6 · Cited by 82
Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200929 · Cited by 74
Liquid biopsy into the clinics: Current evidence and future perspectives
Boukovala, M. A., Westphalen, C. B., & Probst, V. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100146 · Cited by 81
Topham, J. T., O'Callaghan, C. J., Feilotter, H., Kennecke, H. F., Lee, Y. S., Li, W., Banks, K. C., Quinn, K., Renouf, D. J., Jonker, D. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00364 · Cited by 70
Liquid Biopsy to Identify Actionable Genomic Alterations
Ou, S. I., Nagasaka, M., & Zhu, V. W. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199765 · Cited by 77
Therapeutic Targeting of the Colorectal Tumor Stroma
Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 79
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
Randon, G., Fucà, G., Rossini, D., Raimondi, A., Pagani, F., Perrone, F., Tamborini, E., Busico, A., Peverelli, G., Morano, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39525-3 · Cited by 68
Self-citationStein, A., Simnica, D., Schultheiß, C., Scholz, R., Tintelnot, J., Gökkurt, E., von Wenserski, L., Willscher, E., Paschold, L., Sauer, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002844 · Cited by 67
Boustany, L. M., LaPorte, S. L., Wong, L., White, C. W., Vinod, V., Shen, J., Yu, W., Koditek, D., Winter, M. B., Moore, S. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2483 · Cited by 75
Clinical application of circulating tumour DNA in colorectal cancer
Loft, M., To, Y. H., Gibbs, P., & Tie, J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00146-2 · Cited by 77
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor
Orzan, F., Bacco, F. D., Crisafulli, G., Pellegatta, S., Mussolin, B., Siravegna, G., D’Ambrosio, A., Comoglio, P. M., Finocchiaro, G., & Boccaccio, C. (2017) · Stem Cells · doi:10.1002/stem.2703 · Cited by 68
Self-citationResveratrol as sensitizer in colorectal cancer plasticity
Brockmueller, A., Sajeev, A., Koklesová, L., Samuel, S. M., Kubatka, P., Büsselberg, D., Kunnumakkara, A. B., & Shakibaei, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10126-x · Cited by 65
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Zheng, H., Yang, L., Kang, Y., Chen, M., Lin, S., Xiang, Y., Li, C., Dai, X., Huang, X., Liang, G., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22951 · Cited by 62
Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021) · Cells · doi:10.3390/cells10030667 · Cited by 58
Martini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 58
Ortíz, R., Quiñonero, F., García-Pinel, B., Fuel, M., Mesas, C., Cabeza, L., Melguizo, C., & Prados, J. C. (2021) · Cancers · doi:10.3390/cancers13092058 · Cited by 64
Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers
Alese, O. B., Cook, N., Franco, A. O., Ulanja, M. B., Tan, L., & Tie, J. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349143 · Cited by 59
Circulating tumor cells in clinical research and monitoring patients with colorectal cancer
Burz, C. C., Pop, V.-V., Buiga, R., Sur, D. G., Samaşcă, G., Aldea, C. O., & Lupan, I. (2018) · Oncotarget · doi:10.18632/oncotarget.25337 · Cited by 58
Kim, T. W., Peeters, M., Thomas, A., Gibbs, P., Hool, K., Zhang, J., Ang, A. L., Bach, B. A., & Price, T. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3377 · Cited by 60
The importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15420 · Cited by 53
Wang, X., Jiang, W., Du, Y., Dongqi, Z., Zhang, J., Fang, C., Fang, Y., & Chen, Z.-S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100884 · Cited by 55
Goldberg, R. M., Montagut, C., Wainberg, Z. A., Ronga, P., Audhuy, F., Taieb, J., Stintzing, S., Siena, S., & Santini, D. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000353 · Cited by 50
Self-citationMolecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Martini, G., Dienstmann, R., Ros, J., Baraibar, I., Cuadra‐Urteaga, J. L., Salvà, F., Ciardiello, D., Mulet-Margalef, N., Argilés, G., Tabernero, J. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936089 · Cited by 62
Sunakawa, Y., Nakamura, M., Ishizaki, M., Kataoka, M., Satake, H., Kitazono, M., Yanagisawa, H., Kawamoto, Y., Kuramochi, H., Ohori, H., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00109 · Cited by 54
Helden, E. J. V., Angus, L., van Oordt, C. W. M. D. H., Heideman, D. A. M., Boon, E., van Es, S. C., Radema, S. A., van Herpen, C. M. L., de Groot, D. J. A., de Vries, E. G. E., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12550 · Cited by 83
Circulating tumour DNA, a promising biomarker for the management of colorectal cancer
Khakoo, S. S., Georgiou, A., Gerlinger, M., Cunningham, D., & Starling, N. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.002 · Cited by 52
Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer
Akbarzadeh-Khiavi, M., Safary, A., Barar, J., Ajoolabady, A., Somi, M. H., & Omidi, Y. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03305-z · Cited by 48
Callesen, L. B., Hamfjord, J., Boysen, A. K., Pallisgaard, N., Guren, T. K., Kure, E. H., & Spindler, K. G. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01816-4 · Cited by 47
Vidal, J., Fernández‐Rodríguez, C., Casadevall, D., Alfonso, P. G., Páez, D., Guix, M., Alonso, V., Cano, M. T., Santos, C., Durán, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1696 · Cited by 47
Self-citationJohnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 45
Self-citationUnveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 46
Self-citationJohnson, B., Loree, J. M., Jacome, A. A. D. A., Mendis, S. R., Syed, M., Morris, V. K., Parseghian, C. M., Dasari, A. N., Pant, S., Raymond, V. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00102 · Cited by 44
PRSS contributes to cetuximab resistance in colorectal cancer
Tan, Z.-L., Gao, L., Wang, Y., Yin, H., Xi, Y., Wu, X., Shao, Y., Qiu, W., Du, P., Shen, W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5576 · Cited by 40
Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma
Hirotsu, Y., Otake, S., Ohyama, H., Amemiya, K., Higuchi, R., Oyama, T., Mochizuki, H., Goto, T., & Omata, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60361-3 · Cited by 42
Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT
Zhang, L., Yang, J., Huang, J., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · Chem · doi:10.1016/j.chempr.2023.12.019 · Cited by 39
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 40
Development of circulating tumour DNA analysis for gastrointestinal cancers
Nakamura, Y., & Shitara, K. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000600 · Cited by 34
Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue
Loria, R., Vici, P., Lisa, F. S. D., Soddu, S., Maugeri‐Saccà, M., & Bon, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877380 · Cited by 41
Sun, C., Han, C., Jiang, Y., Han, N., Zhang, M., Li, G., & Qiao, Q. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188932 · Cited by 31
EGFRAmplification in Metastatic Colorectal Cancer
Randon, G., Yaeger, R. D., Hechtman, J. F., Manca, P., Fucà, G., Walch, H. S., Lee, J., Élez, E., Seligmann, J. F., Mussolin, B., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab069 · Cited by 35
Self-citationPuzzo, M., Santo, M. D., Morelli, C., Leggio, A., Catalano, S., & Pasqua, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031313 · Cited by 35
Tardito, S., Matis, S., Zocchi, M. R., Benelli, R., & Poggi, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137131 · Cited by 34
Qu, X., Hamidi, H., Johnson, R. M., Sokol, E. S., Lin, E., Eng, C., Kim, T.-W., Bendell, J. C., Sivakumar, S., Kaplan, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59588-3 · Cited by 37
Grandal, M. M., Havrylov, S., Poulsen, T. T., Koefoed, K., Dahlman, A., Galler, G. R., Conrotto, P., Collins, S., Eriksen, K. W., Kaufman, D. W., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0374 · Cited by 28
Brunsell, T. H., Sveen, A., Bjørnbeth, B. A., Røsok, B. I., Danielsen, S. A., Brudvik, K. W., Berg, K. C. G., Johannessen, B., Cengija, V., Abildgaard, A., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.09.003 · Cited by 29
Yamada, T., Matsuda, A., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., Kuriyama, S., Koizumi, M., Shinji, S., Yokoyama, Y., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01691-0 · Cited by 36
Xu, X., Yu, Y., Shen, M., Liu, M., Wu, S., Liang, L., Huang, F., Zhang, C., Guo, W., & Liu, T. (2020) · BMC Cancer · doi:10.1186/s12885-020-07516-7 · Cited by 29
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
Bignucolo, A., Mattia, E. D., Cecchin, E., Roncato, R., & Toffoli, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071522 · Cited by 29
Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer
Prieto‐Potín, I., Montagut, C. O., Bellosillo, B., Evans, M., Smith, M. R., Melchior, L. C., Werner, R., Bennett, M., Pennati, V., Castiglione, F., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.008 · Cited by 25
Self-citationWang, B., Wu, S., Huang, F., Shen, M., Jiang, H., Yu, Y., Yu, Q., Yang, Y., Zhao, Y., Zhou, Y., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0142 · Cited by 25
Holz, A., Paul, B., Zapf, A., Pantel, K., & Joosse, S. A. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102999 · Cited by 27
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 23
The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance
Chen, Z., Wang, G., Guo, M., Zhu, N., Chen, X., Yan, Y., Li, N., & Yu, W. (2024) · Cancer Control · doi:10.1177/10732748241274196 · Cited by 25
Unseld, M., Belic, J., Pierer, K., Zhou, Q. X., Moser, T., Bauer, R., Piringer, G., Gerger, A., Siebenhüner, A. R., Speicher, M. R., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33303 · Cited by 23
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer
Morris, V. K., & Strickler, J. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-070119-120448 · Cited by 23
Ros, J., Baraibar, I., Martini, G., Salvà, F., Gonzalez, N. S., Cuadra‐Urteaga, J. L., Dienstmann, R., Tabernero, J. M., & Élez, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00913-5 · Cited by 25
Metadata
- Authors
- Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., Valtorta, E., Vidal, J., Bellosillo, B., Germano, G., Pietrantonio, F., Ponzetti, A., Albanell, J., Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Montagut, C., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Hospital Del Mar (ES)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- University of Milan (IT)
- Corresponding author
- Montagut, Clara
- Bardelli, Alberto
- ORCID
- Venue
- Nature Communications
- Published
- 2016-12-08
- Volume
- 7
- Issue
- 1
- Pages
- 13665-13665
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5155160
- OpenAlex
- W2560160922
- Cited by
- 214
- References
- 48
- Citations by year
- 2026: 15 · 2025: 10 · 2024: 16 · 2023: 24 · 2022: 30 · 2021: 24 · 2020: 24 · 2019: 29 · 2018: 23 · 2017: 17 · 2016: 1
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
- Funders
- European Commission (635342, 115749, 602901)
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro (16788)
- Fondazione Oncologia Niguarda Onlus
- Instituto de Salud Carlos III (RD12/0036/0051, DTS15/00048, 2014SGR740, PIE15/00008, PI15/00457, PI15/00146, 00048)
- European Regional Development Fund (PIE15/00008, PI15/00146, RD12/0036/0051)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, EGFR inhibition, RAS mutations, cetuximab, panitumumab, anti-EGFR monoclonal antibody, drug resistance, clonal evolution, progression-free survival, tumor shrinkage
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Genes, ras, Colorectal Neoplasms, Genes, erbB-1, Drug Resistance, Neoplasm, Clonal Evolution, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.